Skip to main content

Peer Review reports

From: INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Original Submission
5 Mar 2020 Submitted Original manuscript
6 Apr 2020 Reviewed Reviewer Report
10 Apr 2020 Reviewed Reviewer Report
27 Apr 2020 Author responded Author comments - Cornelis M. van Tilburg
22 May 2020 Author responded Author comments - Cornelis M. van Tilburg
Resubmission - Version 2
27 Apr 2020 Submitted Manuscript version 2
Publishing
27 May 2020 Editorially accepted
5 Jun 2020 Article published 10.1186/s12885-020-07008-8

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us